Chemistry: natural resins or derivatives; peptides or proteins; – Peptides of 3 to 100 amino acid residues – 8 to 10 amino acid residues in defined sequence
Reexamination Certificate
2001-06-02
2004-11-16
Huff, Sheela J. (Department: 1642)
Chemistry: natural resins or derivatives; peptides or proteins;
Peptides of 3 to 100 amino acid residues
8 to 10 amino acid residues in defined sequence
C530S327000, C530S326000, C514S016700, C514S015800, C514S014800, C514S013800
Reexamination Certificate
active
06818741
ABSTRACT:
FIELD OF THE INVENTION
The subject invention is directed generally to alpha-fetoprotein, and more particularly to peptides derived from alpha-fetoprotein and their use to treat and/or prevent cancers, including breast cancer.
BACKGROUND OF THE INVENTION
Throughout this application various publications are referenced, many in parenthesis. Full citations for each of these publications are provided at the end of the Detailed Description. The disclosures of each of these publications in their entireties are hereby incorporated by reference in this application.
Every year in the U.S., 180,000 new cases of breast cancer are diagnosed and approximately 60% of these are ER+ (Martin et al. 1994). Moreover, every year there are a substantial number of breast cancer recurrences and many of these are ER+. Tamoxifen has been the mainstay for medical treatment of ER+ breast cancer and has provided significant clinical benefit (Fisher et al. 1989; Fisher et al. 1998). However, there is a substantial number of ER+ breast cancers that are refractory to tamoxifen due to either intrinsic or acquired resistance. New treatments for these ER+, tamoxifen-refractory breast cancers are needed, and some promising agents are currently being evaluated in clinical trial. Letrozole, which blocks estrogen synthesis by inhibiting aromatase, and goserelin, which stifles ovarian release of estrogen by inhibiting gonadotropin release, are both being tested for this purpose (Goss et al. 2001; Nystedt et al. 2000).
Several population and epidemiologic studies as well as laboratory studies have indicated that alpha-fetoprotein (AFP) interferes with estrogen-dependent responses, including the growth-promoting effects of estrogen on breast cancer (Bennett et al. 1998). For example, Couinaud et al. (1973) have reported that women with AFP-secreting hepatomas develop amenorrhea which self-corrects following removal of the hepatoma, and Mizejewski et al. (1983) have shown that AFP inhibits the responsiveness of the uterus to estrogen. Jacobson et al. (1989) and Richardson et al. (1998) have shown that elevated levels of AFP during pregnancy are associated with subsequent reduction in lifetime risk for breast cancer, and Jacobson et al. have hypothesized that this could be caused by a diminution in estrogen-dependent breast cancers (Jacobson et al. 1989). Sonnenschein et al. (1980) have shown in rats that an AFP-secreting hepatoma prevents the growth of an estrogen-dependent breast cancer in the same rat. Finally, it has been shown that AFP purified from a human hepatoma culture and then injected into tumor-bearing immune-deficient mice stopped the growth of estrogen-receptor-positive (ER+), but not estrogen-receptor-negative (ER−), human breast cancer xenografts in these mice, and did so by a mechanism different from that of tamoxifen (Bennett et al. 1998).
More recently, the active site of AFP responsible for its antiestrotrophic activity has been identified (Mesfin et al. 2000). It consists of amino acids 472-479 (SEQ ID NO: 6: EMTPVNPG), an 8-mer sequence in the 580-amino acid AFP molecule.
Aggregation of proteins and peptides has been seen with full length AFP as well as with subunits of AFP. Wu et al. (1985) showed that AFP tends to form aggregates, which may contribute to its loss of anti-estrotrophic activity during storage. Eisele et al. (2001) reported that oligomers of various sizes formed during storage of a 34-mer peptide (amino acids 447-480) derived from AFP. Similar aggregation behavior has been seen with a number of other protein and peptide pharmaceuticals including human interferon gamma (Kendrick et al. 1998), human calcitonin (Bauer et al. 1994), insulin (Sluzky et al. 1991), and synthetic beta-amyloid peptide (Hilbich et al. 1991; Christmanson et al. 1993; Halverson et al. 1990). Hughes et al. (1996) and Hilbich et al. (1992) reported inhibition of amyloid peptide aggregation by substitution of hydrophobic phenylalanine with hydrophilic threonine or by adding poly-lysine at the carboxy-terminus of the amyloid peptide.
As indicated above, tamoxifen is currently the most widely used agent for the treatment of estrogen-responsive breast cancers and has provided significant benefit to women with this disease (Fisher et al. 1989; Fisher et al. 1998). However, one problem connected with its clinical use is that not all ER+ breast cancers are sensitive to this drug. About one-third to one-sixth (depending on the lab cutoff for ER positivity) of the ER+, newly diagnosed breast cancers do not respond to tamoxifen (Jensen et al. 1996). Moreover, it is not uncommon that women whose disease is being successfully managed by tamoxifen therapy will in time experience recurrence during treatment apparently because their tumor has acquired resistance to the drug. Because these two groups constitute a substantial number of woman whose disease fails to respond to tamoxifen therapy, it is important to seek alternative treatment methods.
SUMMARY OF THE INVENTION
The subject invention addresses the need for methods of treatment and prevention of breast cancer, and other cancers, by providing a peptide of eight to twenty amino acids in length which comprises a hydrophilic analog of an alpha-fetoprotein peptide having SEQ ID NO: 6: EMTPVNPG. The peptides may be linear, but are preferably cyclic. The peptides may be provided as dimers or other multimers. A composition comprising the peptide, an antibody that specifically binds to the peptide, a method of reducing estrogen-stimulated growth of cells using the peptide, as well as a method of treating or preventing cancer, such as breast cancer, are also provided. The treatment or prevention method can include the use of tamoxifen therapy in combination with the peptide therapy.
REFERENCES:
patent: 5532167 (1996-07-01), Cantley et al.
patent: 5674842 (1997-10-01), Mizejewski
patent: 5707963 (1998-01-01), Mizejewski
patent: 6306832 (2001-10-01), Pietras
patent: 6348567 (2002-02-01), Krystal et al.
Vakharia et al, Breast Cancer Research and Treatment vol. 63 p. 41 (2000).*
Bennett, et al. (2001). Abstract Only “An &agr;-fetoprotein-Derived Peptide Inhibits Estrogen Receptor Positive Breast Cancers, Sensitive and Resistant to Tamoxifen”Proc. Amer. Assoc. Can. Res.42: 238.
Eisele, et al. (2001).J. Pept. Res.57:29-38.
Eisele, et al. (2001).J. Pept. Res.57:539-546.
Gekonge, et al. (2001). Abstract OnlyProc. Amer. Assoc. Can. Res.42: 239.
Jacobson, et al. (2000). Abstract from International Society for Preventive Oncology (ISPO) Meeting, Oct. 28-31, 2000, http://www.cancerprev.org/Meetings/2000/Abstracts/ Show?Num=556.
Mesfin, et al. (2000).Biochim. Et. Biophys. Act.1501: 33-43.
Mesfin, et al. (2000). Abstract OnlyProc. Amer. Assoc. Can Res.41:375.
Mesfin, et al. (2001). Abstract OnlyProc. Amer. Assoc. Can. Res42: 778.
Mesfin, et al. (2001).J. Pept. Res.58: 246-256.
Mizejewski, et al. (1996).Molec. Cell. Endo.118: 15-23.
Vakharia, et al. (2000). Abstract Only.Breast. Can. Res. Treat.63:41-52.
Duphinee, et al. (2000). Abstract Only.Breast. Can. Res. Treat64:109.
MacColl, et al. (2001). Abstract Only,Biochim. Biophys. ACTA Gen. Subj.1528(2-3): 127-134.
Li, et al. (2001). Abstract Only.Clin. Chim. ACTA313:15-19.
Andersen Thomas T.
Bennett James A.
Jacobson Herbert I.
Mesfin Fassil B.
Biswas, Esq. Naomi S.
CLF Medical Technology Acceleration Program, Inc.
Elrifi, Esq. Ivor R.
Huff Sheela J.
Mintz Levin Cohn Ferris Glovsky and Popeo P.C.
LandOfFree
Alpha-fetoprotein peptides and uses therof does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Alpha-fetoprotein peptides and uses therof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Alpha-fetoprotein peptides and uses therof will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3336309